DXC Technology’s fourth quarter results were met with a negative market response, reflecting investor concerns despite stable headline revenue and a significant non-GAAP earnings per share surprise.

Welcome back. I’m Matt Bird your host. We are coming off another panel and I’ve got with me next the chief medical officer for DXC Technologies of North America, George Mathew. George, how are you ...

Hello and welcome to the DXC Technology Fourth Quarter and Fiscal Year End 2025 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there ...